Armata Pharmaceuticals received an upgrade following an upward trend in its earnings estimates.
3 reports, 1 independent
Updated Aug 1
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Armata Pharmaceuticals received an upgrade following an upward trend in its earnings estimates.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Armata Pharmaceuticals (United States)
company in Los Angeles, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksAll You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy Investors might want to bet on Armata Pharmaceuticals, Inc. (ARMP), as it has been recently upgraded to a Zacks Rank #2
- ZacksArmata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate